Is COWZ ETF a Good Investment?
There’s a reason even Warren Buffett advocates his heirs to…
Sell
43
BPMC Quote, Financials, Valuation and Earnings
Last price:
$102.47
Seasonality move
:
5.27%
Day range:
$90.23 - $103.81
52-week range:
$72.24 - $121.90
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
14.93x
P/B ratio:
20.97x
Volume:
2.1M
Avg. volume:
677K
1-year change:
24.64%
Market cap:
$6.6B
Revenue:
$249.4M
EPS (TTM):
-$2.11
Analysts' Opinion
-
Consensus RatingBlueprint Medicines has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 5 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $125.00, Blueprint Medicines has an estimated upside of 20.94% from its current price of $103.36.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $81.00 representing 21.63% downside risk from its current price of $103.36.
Fair Value
-
According to the consensus of 15 analysts, Blueprint Medicines has 20.94% upside to fair value with a price target of $125.00 per share.
BPMC vs. S&P 500
-
Over the past 5 trading days, Blueprint Medicines has overperformed the S&P 500 by 18.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Blueprint Medicines does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Blueprint Medicines has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Blueprint Medicines reported revenues of $128.2M.
Earnings Growth
-
Blueprint Medicines has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Blueprint Medicines reported earnings per share of -$0.89.
Enterprise value:
6.2B
EV / Invested capital:
--
Price / LTM sales:
14.93x
EV / EBIT:
--
EV / Revenue:
14.31x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-24.82x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$421.4M
Return On Assets:
-11.44%
Net Income Margin (TTM):
-29.48%
Return On Equity:
-50.13%
Return On Invested Capital:
-23.14%
Operating Margin:
-38.21%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $272.3M | $216.2M | $434.4M | $56.6M | $128.2M | |
| Gross Profit | $251.8M | $203.1M | $421.4M | $53.8M | $126.3M | |
| Operating Income | -$692.2M | -$524.8M | -$276M | -$127.2M | -$49M | |
| EBITDA | -$685.3M | -$486.7M | -$75.6M | -$117.5M | -$33.4M | |
| Diluted EPS | -$12.10 | -$9.19 | -$2.11 | -$2.20 | -$0.89 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $841.7M | $771.8M | $1.2B | $808.2M | $854.8M | |
| Total Assets | $1.6B | $1.5B | $1.5B | $1.1B | $1.2B | |
| Current Liabilities | $110.1M | $119.7M | $175.5M | $197.4M | $257.7M | |
| Total Liabilities | $238.2M | $230.2M | $818.1M | $902.7M | $886.5M | |
| Total Equity | $1.3B | $1.2B | $640.3M | $202.6M | $313.1M | |
| Total Debt | -- | -- | $138.4M | $238.4M | $386.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$395M | -$479.3M | -$242.2M | -$104.5M | -$13.6M | |
| Cash From Investing | -$443.2M | $142M | -$2.4M | -$9.6M | $30M | |
| Cash From Financing | $577.2M | $106.2M | $278.9M | $98.4M | $18.4M | |
| Free Cash Flow | -$661.8M | -$492.2M | -$250.5M | -$110.7M | -$13.7M | |
BPMC
Sector
Market Cap
$6.6B
$46.7M
Price % of 52-Week High
84.79%
46.54%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
24.64%
-33.88%
Beta (5-Year)
0.610
0.752
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$91.01
200-day SMA
Buy
Level
$96.81
Bollinger Bands (100)
Buy
Level
87.04 - 95.76
Chaikin Money Flow
Buy
Level
26M
20-day SMA
Buy
Level
$91.26
Relative Strength Index (RSI14)
Buy
Level
65.19
ADX Line
Buy
Level
32.97
Williams %R
Sell
Level
-2.514
50-day SMA
Buy
Level
$93.56
MACD (12, 26)
Buy
Level
0.02
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
28.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.0379)
Sell
CA Score
(Annual)
Level (-3.2563)
Sell
Beneish M-Score
(Annual)
Level (-2.0419)
Buy
Momentum Score
Level (8)
Sell
Ohlson Score
Level (4.1676)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.
Stock Forecast FAQ
In the current month, BPMC has received 9 Buy ratings 5 Hold ratings, and 1 Sell ratings. The BPMC average analyst price target in the past 3 months is $125.00.
-
Where Will Blueprint Medicines Stock Be In 1 Year?
According to analysts, the consensus estimate is that Blueprint Medicines share price will rise to $125.00 per share over the next 12 months.
-
What Do Analysts Say About Blueprint Medicines?
Analysts are divided on their view about Blueprint Medicines share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Blueprint Medicines is a Sell and believe this share price will drop from its current level to $81.00.
-
What Is Blueprint Medicines's Price Target?
The price target for Blueprint Medicines over the next 1-year time period is forecast to be $125.00 according to 15 Wall Street analysts, 9 of them rate the stock a Buy, 1 rates the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is BPMC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Blueprint Medicines is a Buy. 9 of 15 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of BPMC?
You can purchase shares of Blueprint Medicines via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Blueprint Medicines shares.
-
What Is The Blueprint Medicines Share Price Today?
Blueprint Medicines was last trading at $102.47 per share. This represents the most recent stock quote for Blueprint Medicines. Yesterday, Blueprint Medicines closed at $103.36 per share.
-
How To Buy Blueprint Medicines Stock Online?
In order to purchase Blueprint Medicines stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
3 Stocks Buffett Is Betting On
Warren Buffett appeared to take a hard look at the…
Why Did Buffett Sell So Much Last Year?
In 2024, value investing legend Warren Buffett did the seemingly…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.5T
P/E Ratio: 39x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 112x
Sell
40
Is MSFT Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
61
ITCI alert for Jan 14
Intra-Cellular Therapies [ITCI] is down 0.26% over the past day.
Sell
30
ESTA alert for Jan 14
Establishment Labs Holdings [ESTA] is down 1.51% over the past day.
Buy
72
DJT alert for Jan 14
Trump Media & Technology Group [DJT] is down 8.25% over the past day.
